US20210145348A1 - Compositions and methods for a universal clinical test for olfactory dysfunction - Google Patents
Compositions and methods for a universal clinical test for olfactory dysfunction Download PDFInfo
- Publication number
- US20210145348A1 US20210145348A1 US16/628,075 US201816628075A US2021145348A1 US 20210145348 A1 US20210145348 A1 US 20210145348A1 US 201816628075 A US201816628075 A US 201816628075A US 2021145348 A1 US2021145348 A1 US 2021145348A1
- Authority
- US
- United States
- Prior art keywords
- methyl
- ethyl
- smell
- compounds
- acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 201
- 238000000034 method Methods 0.000 title claims abstract description 41
- 238000012360 testing method Methods 0.000 title abstract description 207
- 230000004064 dysfunction Effects 0.000 title description 14
- 230000035945 sensitivity Effects 0.000 claims abstract description 36
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 claims description 141
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 claims description 129
- HUAZGNHGCJGYNP-UHFFFAOYSA-N propyl butyrate Chemical compound CCCOC(=O)CCC HUAZGNHGCJGYNP-UHFFFAOYSA-N 0.000 claims description 129
- 235000019645 odor Nutrition 0.000 claims description 127
- CHLICZRVGGXEOD-UHFFFAOYSA-N 1-Methoxy-4-methylbenzene Chemical compound COC1=CC=C(C)C=C1 CHLICZRVGGXEOD-UHFFFAOYSA-N 0.000 claims description 101
- VZWGRQBCURJOMT-UHFFFAOYSA-N Dodecyl acetate Chemical compound CCCCCCCCCCCCOC(C)=O VZWGRQBCURJOMT-UHFFFAOYSA-N 0.000 claims description 101
- ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 2-octanone Chemical compound CCCCCCC(C)=O ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 0.000 claims description 97
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 97
- XUPYJHCZDLZNFP-UHFFFAOYSA-N butyl butanoate Chemical compound CCCCOC(=O)CCC XUPYJHCZDLZNFP-UHFFFAOYSA-N 0.000 claims description 90
- WTWBUQJHJGUZCY-UHFFFAOYSA-N cuminaldehyde Chemical compound CC(C)C1=CC=C(C=O)C=C1 WTWBUQJHJGUZCY-UHFFFAOYSA-N 0.000 claims description 89
- 150000001875 compounds Chemical class 0.000 claims description 87
- RGXWDWUGBIJHDO-UHFFFAOYSA-N ethyl decanoate Chemical compound CCCCCCCCCC(=O)OCC RGXWDWUGBIJHDO-UHFFFAOYSA-N 0.000 claims description 86
- RMZIOVJHUJAAEY-UHFFFAOYSA-N Allyl butyrate Chemical compound CCCC(=O)OCC=C RMZIOVJHUJAAEY-UHFFFAOYSA-N 0.000 claims description 85
- 238000010790 dilution Methods 0.000 claims description 85
- 239000012895 dilution Substances 0.000 claims description 85
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims description 83
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims description 79
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 claims description 73
- TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 claims description 68
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims description 67
- PGMYKACGEOXYJE-UHFFFAOYSA-N pentyl acetate Chemical compound CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 claims description 67
- NCDCLPBOMHPFCV-UHFFFAOYSA-N hexyl hexanoate Chemical compound CCCCCCOC(=O)CCCCC NCDCLPBOMHPFCV-UHFFFAOYSA-N 0.000 claims description 66
- PFYHAAAQPNMZHO-UHFFFAOYSA-N Methyl 2-methoxybenzoate Chemical compound COC(=O)C1=CC=CC=C1OC PFYHAAAQPNMZHO-UHFFFAOYSA-N 0.000 claims description 65
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 65
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 64
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 claims description 64
- ZFMSMUAANRJZFM-UHFFFAOYSA-N Estragole Chemical compound COC1=CC=C(CC=C)C=C1 ZFMSMUAANRJZFM-UHFFFAOYSA-N 0.000 claims description 60
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims description 60
- SJWKGDGUQTWDRV-UHFFFAOYSA-N 2-Propenyl heptanoate Chemical compound CCCCCCC(=O)OCC=C SJWKGDGUQTWDRV-UHFFFAOYSA-N 0.000 claims description 59
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 claims description 58
- YTHRBOFHFYZBRJ-UHFFFAOYSA-N (2-methyl-5-prop-1-en-2-yl-1-cyclohex-2-enyl) acetate Chemical compound CC(=O)OC1CC(C(C)=C)CC=C1C YTHRBOFHFYZBRJ-UHFFFAOYSA-N 0.000 claims description 57
- OUGPMNMLWKSBRI-UHFFFAOYSA-N Hexyl formate Chemical compound CCCCCCOC=O OUGPMNMLWKSBRI-UHFFFAOYSA-N 0.000 claims description 53
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 claims description 52
- RCSBILYQLVXLJG-UHFFFAOYSA-N 2-Propenyl hexanoate Chemical compound CCCCCC(=O)OCC=C RCSBILYQLVXLJG-UHFFFAOYSA-N 0.000 claims description 51
- STZUZYMKSMSTOU-UHFFFAOYSA-N 3-Octyl acetate Chemical compound CCCCCC(CC)OC(C)=O STZUZYMKSMSTOU-UHFFFAOYSA-N 0.000 claims description 49
- YYZUSRORWSJGET-UHFFFAOYSA-N ethyl octanoate Chemical compound CCCCCCCC(=O)OCC YYZUSRORWSJGET-UHFFFAOYSA-N 0.000 claims description 47
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 46
- ZAJNGDIORYACQU-UHFFFAOYSA-N decan-2-one Chemical compound CCCCCCCCC(C)=O ZAJNGDIORYACQU-UHFFFAOYSA-N 0.000 claims description 46
- KEFJLCGVTHRGAH-UHFFFAOYSA-N 2-acetyl-5-methylfuran Chemical compound CC(=O)C1=CC=C(C)O1 KEFJLCGVTHRGAH-UHFFFAOYSA-N 0.000 claims description 44
- -1 2-acetyl-5-methylfuran 2-decanone 2-ethyl-1-hexanol 2-nonanone 2-phenylethanol 6-acetyl-1,1,2,4,4,7-hexamethyltetralin acetophenone Chemical compound 0.000 claims description 44
- BKAWJIRCKVUVED-UHFFFAOYSA-N 5-(2-hydroxyethyl)-4-methylthiazole Chemical compound CC=1N=CSC=1CCO BKAWJIRCKVUVED-UHFFFAOYSA-N 0.000 claims description 44
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 claims description 44
- AYJXHIDNNLJQDT-UHFFFAOYSA-N 2,6,6-Trimethyl-2-cyclohexene-1,4-dione Chemical compound CC1=CC(=O)CC(C)(C)C1=O AYJXHIDNNLJQDT-UHFFFAOYSA-N 0.000 claims description 41
- CRZQGDNQQAALAY-UHFFFAOYSA-N Methyl benzeneacetate Chemical compound COC(=O)CC1=CC=CC=C1 CRZQGDNQQAALAY-UHFFFAOYSA-N 0.000 claims description 41
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 41
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 claims description 41
- CRBJBYGJVIBWIY-UHFFFAOYSA-N 2-isopropylphenol Chemical compound CC(C)C1=CC=CC=C1O CRBJBYGJVIBWIY-UHFFFAOYSA-N 0.000 claims description 40
- OUDFNZMQXZILJD-UHFFFAOYSA-N 5-methyl-2-furaldehyde Chemical compound CC1=CC=C(C=O)O1 OUDFNZMQXZILJD-UHFFFAOYSA-N 0.000 claims description 38
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 claims description 38
- UPMAOXLCTXPPAG-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol Chemical compound C1CCCC2CC(O)CCC21 UPMAOXLCTXPPAG-UHFFFAOYSA-N 0.000 claims description 37
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 37
- GKGOLPMYJJXRGD-UHFFFAOYSA-N 2-methyl-4-propyl-1,3-oxathiane Chemical compound CCCC1CCOC(C)S1 GKGOLPMYJJXRGD-UHFFFAOYSA-N 0.000 claims description 36
- SRZXCOWFGPICGA-UHFFFAOYSA-N 1,6-Hexanedithiol Chemical compound SCCCCCCS SRZXCOWFGPICGA-UHFFFAOYSA-N 0.000 claims description 35
- 229940077398 4-methyl anisole Drugs 0.000 claims description 35
- ZERULLAPCVRMCO-UHFFFAOYSA-N Dipropyl sulfide Chemical compound CCCSCCC ZERULLAPCVRMCO-UHFFFAOYSA-N 0.000 claims description 35
- HDJLSECJEQSPKW-UHFFFAOYSA-N Methyl 2-Furancarboxylate Chemical compound COC(=O)C1=CC=CO1 HDJLSECJEQSPKW-UHFFFAOYSA-N 0.000 claims description 35
- YZRXRLLRSPQHDK-UHFFFAOYSA-N 6-Hexyltetrahydro-2H-pyran-2-one Chemical compound CCCCCCC1CCCC(=O)O1 YZRXRLLRSPQHDK-UHFFFAOYSA-N 0.000 claims description 33
- VKCYHJWLYTUGCC-UHFFFAOYSA-N nonan-2-one Chemical compound CCCCCCCC(C)=O VKCYHJWLYTUGCC-UHFFFAOYSA-N 0.000 claims description 33
- MHJSWOZJMPIGJQ-UHFFFAOYSA-N 2-(1-methylpropyl)thiazole Chemical compound CCC(C)C1=NC=CS1 MHJSWOZJMPIGJQ-UHFFFAOYSA-N 0.000 claims description 32
- RHLVCLIPMVJYKS-UHFFFAOYSA-N 3-octanone Chemical compound CCCCCC(=O)CC RHLVCLIPMVJYKS-UHFFFAOYSA-N 0.000 claims description 32
- PETRWTHZSKVLRE-UHFFFAOYSA-N 2-Methoxy-4-methylphenol Chemical compound COC1=CC(C)=CC=C1O PETRWTHZSKVLRE-UHFFFAOYSA-N 0.000 claims description 31
- PRNCMAKCNVRZFX-UHFFFAOYSA-N 3,7-dimethyloctan-1-ol Chemical compound CC(C)CCCC(C)CCO PRNCMAKCNVRZFX-UHFFFAOYSA-N 0.000 claims description 31
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 claims description 31
- KBSVBCHYXYXDAG-UHFFFAOYSA-N 3-acetyl-2,5-dimethylfuran Chemical compound CC(=O)C=1C=C(C)OC=1C KBSVBCHYXYXDAG-UHFFFAOYSA-N 0.000 claims description 30
- WAPNOHKVXSQRPX-UHFFFAOYSA-N 1-phenylethanol Chemical compound CC(O)C1=CC=CC=C1 WAPNOHKVXSQRPX-UHFFFAOYSA-N 0.000 claims description 29
- 239000005792 Geraniol Substances 0.000 claims description 29
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims description 29
- 229940113087 geraniol Drugs 0.000 claims description 29
- FKUPPRZPSYCDRS-UHFFFAOYSA-N Cyclopentadecanolide Chemical compound O=C1CCCCCCCCCCCCCCO1 FKUPPRZPSYCDRS-UHFFFAOYSA-N 0.000 claims description 27
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 claims description 26
- VMUXSMXIQBNMGZ-UHFFFAOYSA-N 3,4-dihydrocoumarin Chemical compound C1=CC=C2OC(=O)CCC2=C1 VMUXSMXIQBNMGZ-UHFFFAOYSA-N 0.000 claims description 26
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims description 26
- GAEKPEKOJKCEMS-UHFFFAOYSA-N gamma-valerolactone Chemical compound CC1CCC(=O)O1 GAEKPEKOJKCEMS-UHFFFAOYSA-N 0.000 claims description 26
- UHEPJGULSIKKTP-UHFFFAOYSA-N sulcatone Chemical compound CC(C)=CCCC(C)=O UHEPJGULSIKKTP-UHFFFAOYSA-N 0.000 claims description 26
- QKPSYARWSBJEDY-UHFFFAOYSA-N 2-Phenylethyl 2-furancarboxylate Chemical compound C=1C=COC=1C(=O)OCCC1=CC=CC=C1 QKPSYARWSBJEDY-UHFFFAOYSA-N 0.000 claims description 25
- FLUWAIIVLCVEKF-UHFFFAOYSA-N 2-Methyl-1-phenyl-2-propanyl acetate Chemical compound CC(=O)OC(C)(C)CC1=CC=CC=C1 FLUWAIIVLCVEKF-UHFFFAOYSA-N 0.000 claims description 24
- YGCXQTYRSKMILM-UHFFFAOYSA-N 3,4-diaminobenzohydrazide Chemical compound NNC(=O)C1=CC=C(N)C(N)=C1 YGCXQTYRSKMILM-UHFFFAOYSA-N 0.000 claims description 24
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 24
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 24
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 claims description 24
- MIYFJEKZLFWKLZ-UHFFFAOYSA-N Phenylmethyl benzeneacetate Chemical compound C=1C=CC=CC=1COC(=O)CC1=CC=CC=C1 MIYFJEKZLFWKLZ-UHFFFAOYSA-N 0.000 claims description 24
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 23
- PQLMXFQTAMDXIZ-UHFFFAOYSA-N isoamyl butyrate Chemical compound CCCC(=O)OCCC(C)C PQLMXFQTAMDXIZ-UHFFFAOYSA-N 0.000 claims description 23
- 229940107700 pyruvic acid Drugs 0.000 claims description 23
- DNRJTBAOUJJKDY-UHFFFAOYSA-N 2-Acetyl-3,5,5,6,8,8-hexamethyl-5,6,7,8- tetrahydronaphthalene Chemical compound CC(=O)C1=C(C)C=C2C(C)(C)C(C)CC(C)(C)C2=C1 DNRJTBAOUJJKDY-UHFFFAOYSA-N 0.000 claims description 21
- YTHRBOFHFYZBRJ-RYUDHWBXSA-N Carvyl acetate Natural products CC(=O)O[C@H]1C[C@@H](C(C)=C)CC=C1C YTHRBOFHFYZBRJ-RYUDHWBXSA-N 0.000 claims description 21
- IAFQYUQIAOWKSB-UHFFFAOYSA-N Ethyl undecanoate Chemical compound CCCCCCCCCCC(=O)OCC IAFQYUQIAOWKSB-UHFFFAOYSA-N 0.000 claims description 20
- HCRBXQFHJMCTLF-ZCFIWIBFSA-N ethyl (2r)-2-methylbutanoate Chemical compound CCOC(=O)[C@H](C)CC HCRBXQFHJMCTLF-ZCFIWIBFSA-N 0.000 claims description 20
- QMVPMAAFGQKVCJ-JTQLQIEISA-N (-)-Citronellol Chemical compound OCC[C@@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-JTQLQIEISA-N 0.000 claims description 19
- HFZLSTDPRQSZCQ-UHFFFAOYSA-N 1-pyrrolidin-3-ylpyrrolidine Chemical compound C1CCCN1C1CNCC1 HFZLSTDPRQSZCQ-UHFFFAOYSA-N 0.000 claims description 19
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 19
- XKWSWANXMRXDES-UHFFFAOYSA-N 3-methylbutyl octanoate Chemical compound CCCCCCCC(=O)OCCC(C)C XKWSWANXMRXDES-UHFFFAOYSA-N 0.000 claims description 18
- VKJIAEQRKBQLLA-UHFFFAOYSA-N 2-Methoxy-3-methylpyrazine Chemical compound COC1=NC=CN=C1C VKJIAEQRKBQLLA-UHFFFAOYSA-N 0.000 claims description 17
- HVGZQCSMLUDISR-UHFFFAOYSA-N 2-Phenylethyl propanoate Chemical compound CCC(=O)OCCC1=CC=CC=C1 HVGZQCSMLUDISR-UHFFFAOYSA-N 0.000 claims description 17
- 229930192474 thiophene Natural products 0.000 claims description 17
- MDHYEMXUFSJLGV-UHFFFAOYSA-N phenethyl acetate Chemical compound CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 claims description 16
- YXVSKJDFNJFXAJ-UHFFFAOYSA-N 4-cyclohexyl-2-methylbutan-2-ol Chemical compound CC(C)(O)CCC1=CC=CC=C1 YXVSKJDFNJFXAJ-UHFFFAOYSA-N 0.000 claims description 15
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 claims description 14
- YCIXWYOBMVNGTB-UHFFFAOYSA-N 3-methyl-2-pentylcyclopent-2-en-1-one Chemical compound CCCCCC1=C(C)CCC1=O YCIXWYOBMVNGTB-UHFFFAOYSA-N 0.000 claims description 14
- CDJJKTLOZJAGIZ-UHFFFAOYSA-N Tolylacetate Chemical compound CC(=O)OC1=CC=C(C)C=C1 CDJJKTLOZJAGIZ-UHFFFAOYSA-N 0.000 claims description 14
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 claims description 14
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims description 13
- 229930004024 (S)-(-)-citronellol Natural products 0.000 claims description 12
- 235000018285 (S)-(-)-citronellol Nutrition 0.000 claims description 12
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N Citronellol Natural products OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 claims description 12
- CRTCWNPLKVVXIX-UHFFFAOYSA-N 5-(2-Hydroxyethyl)-4-methylthiazole acetate Chemical compound CC(=O)OCCC=1SC=NC=1C CRTCWNPLKVVXIX-UHFFFAOYSA-N 0.000 claims description 11
- DMSHWWDRAYHEBS-UHFFFAOYSA-N dihydrocoumarin Natural products C1CC(=O)OC2=C1C=C(OC)C(OC)=C2 DMSHWWDRAYHEBS-UHFFFAOYSA-N 0.000 claims description 11
- IYEVQBUAWBANLZ-UHFFFAOYSA-N 2-Acetyl-5-methylfuran Natural products CC(=O)C1=CC(C)=CO1 IYEVQBUAWBANLZ-UHFFFAOYSA-N 0.000 claims description 10
- NDUWJHRKDYXRAD-UHFFFAOYSA-N 2-ethoxy-1,3-thiazole Chemical compound CCOC1=NC=CS1 NDUWJHRKDYXRAD-UHFFFAOYSA-N 0.000 claims description 10
- 239000001813 ethyl (2R)-2-methylbutanoate Substances 0.000 claims description 10
- 229940090910 ethyl 2-methylbutyrate Drugs 0.000 claims description 10
- FAHUKNBUIVOJJR-UHFFFAOYSA-N 1-(4-fluorophenyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1C1C2=CC=CN2CCN1 FAHUKNBUIVOJJR-UHFFFAOYSA-N 0.000 claims description 9
- AROCNZZBLCAOPH-UHFFFAOYSA-N 1-methyl-4-prop-2-enoxybenzene Chemical compound CC1=CC=C(OCC=C)C=C1 AROCNZZBLCAOPH-UHFFFAOYSA-N 0.000 claims description 9
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 claims description 9
- GRAORJFMGCQWRN-UHFFFAOYSA-N Butyl undecylenate Chemical compound CCCCOC(=O)CCCCCCCCC=C GRAORJFMGCQWRN-UHFFFAOYSA-N 0.000 claims description 9
- WNVCMFHPRIBNCW-UHFFFAOYSA-N Quercuslactone a Chemical compound CCCCC1OC(=O)CC1C WNVCMFHPRIBNCW-UHFFFAOYSA-N 0.000 claims description 9
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims description 9
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims description 9
- 235000007746 carvacrol Nutrition 0.000 claims description 9
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims description 9
- 230000008447 perception Effects 0.000 claims description 9
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 8
- MUXOBHXGJLMRAB-UHFFFAOYSA-N Dimethyl succinate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 claims description 8
- 239000005770 Eugenol Substances 0.000 claims description 8
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 8
- XPNGNIFUDRPBFJ-UHFFFAOYSA-N alpha-methylbenzylalcohol Natural products CC1=CC=CC=C1CO XPNGNIFUDRPBFJ-UHFFFAOYSA-N 0.000 claims description 8
- 229960002217 eugenol Drugs 0.000 claims description 8
- LOKPJYNMYCVCRM-UHFFFAOYSA-N omega-pentadecalactone Natural products O=C1CCCCCCCCCCCCCCCO1 LOKPJYNMYCVCRM-UHFFFAOYSA-N 0.000 claims description 8
- NMRPBPVERJPACX-UHFFFAOYSA-N (3S)-octan-3-ol Natural products CCCCCC(O)CC NMRPBPVERJPACX-UHFFFAOYSA-N 0.000 claims description 7
- WOFPPJOZXUTRAU-UHFFFAOYSA-N 2-Ethyl-1-hexanol Natural products CCCCC(O)CCC WOFPPJOZXUTRAU-UHFFFAOYSA-N 0.000 claims description 7
- MXPQWTUKCULYHR-UHFFFAOYSA-N 4-phenyl-3-pyridin-3-yl-1h-1,2,4-triazole-5-thione Chemical compound C=1C=CC=CC=1N1C(=S)NN=C1C1=CC=CN=C1 MXPQWTUKCULYHR-UHFFFAOYSA-N 0.000 claims description 7
- 239000001196 ethyl (3R)-3-hydroxyhexanoate Substances 0.000 claims description 7
- 229940094941 isoamyl butyrate Drugs 0.000 claims description 7
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 claims description 7
- 238000013207 serial dilution Methods 0.000 claims description 7
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 claims description 6
- UHOPWFKONJYLCF-UHFFFAOYSA-N 2-(2-sulfanylethyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCS)C(=O)C2=C1 UHOPWFKONJYLCF-UHFFFAOYSA-N 0.000 claims description 6
- MJTPMXWJHPOWGH-UHFFFAOYSA-N 2-Phenoxyethyl isobutyrate Chemical compound CC(C)C(=O)OCCOC1=CC=CC=C1 MJTPMXWJHPOWGH-UHFFFAOYSA-N 0.000 claims description 6
- ZWVHTXAYIKBMEE-UHFFFAOYSA-N 2-hydroxyacetophenone Chemical compound OCC(=O)C1=CC=CC=C1 ZWVHTXAYIKBMEE-UHFFFAOYSA-N 0.000 claims description 6
- JPTPEPVCVXGNJM-UHFFFAOYSA-N 4,5-dimethylfuran-2-carbaldehyde Chemical compound CC=1C=C(C=O)OC=1C JPTPEPVCVXGNJM-UHFFFAOYSA-N 0.000 claims description 6
- 229940102398 methyl anthranilate Drugs 0.000 claims description 6
- 229940017219 methyl propionate Drugs 0.000 claims description 6
- 239000001154 2-(methoxymethyl)pyrazine Substances 0.000 claims description 5
- OHEFFKYYKJVVOX-UHFFFAOYSA-N sulcatol Natural products CC(O)CCC=C(C)C OHEFFKYYKJVVOX-UHFFFAOYSA-N 0.000 claims description 5
- 239000001811 (2R,4R)-2-methyl-4-propyl-1,3-oxathiane Substances 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 claims description 2
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 claims description 2
- LLLXSSKMZWYKPY-UHFFFAOYSA-N CCSCC.CC(=O)c1cccnc1 Chemical compound CCSCC.CC(=O)c1cccnc1 LLLXSSKMZWYKPY-UHFFFAOYSA-N 0.000 claims 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims 1
- 229950011260 betanaphthol Drugs 0.000 claims 1
- 229940049953 phenylacetate Drugs 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 5
- 238000005259 measurement Methods 0.000 abstract description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 157
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 115
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 75
- ONKUXPIBXRRIDU-UHFFFAOYSA-N Diethyl decanedioate Chemical compound CCOC(=O)CCCCCCCCC(=O)OCC ONKUXPIBXRRIDU-UHFFFAOYSA-N 0.000 description 57
- 230000035943 smell Effects 0.000 description 47
- XNCNNDVCAUWAIT-UHFFFAOYSA-N Methyl heptanoate Chemical compound CCCCCCC(=O)OC XNCNNDVCAUWAIT-UHFFFAOYSA-N 0.000 description 46
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 43
- 239000003205 fragrance Substances 0.000 description 42
- 229940067107 phenylethyl alcohol Drugs 0.000 description 39
- 229940117803 phenethylamine Drugs 0.000 description 38
- 238000002474 experimental method Methods 0.000 description 37
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 35
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 33
- WEGYGNROSJDEIW-UHFFFAOYSA-N 3-Acetylpyridine Chemical compound CC(=O)C1=CC=CN=C1 WEGYGNROSJDEIW-UHFFFAOYSA-N 0.000 description 32
- HCRBXQFHJMCTLF-UHFFFAOYSA-N ethyl 2-methylbutyrate Chemical compound CCOC(=O)C(C)CC HCRBXQFHJMCTLF-UHFFFAOYSA-N 0.000 description 27
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 26
- 208000012898 Olfaction disease Diseases 0.000 description 24
- 230000008786 sensory perception of smell Effects 0.000 description 24
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 23
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 22
- JECYUBVRTQDVAT-UHFFFAOYSA-N 2-acetylphenol Chemical compound CC(=O)C1=CC=CC=C1O JECYUBVRTQDVAT-UHFFFAOYSA-N 0.000 description 20
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 20
- 238000013102 re-test Methods 0.000 description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 17
- BTMVHUNTONAYDX-UHFFFAOYSA-N butyl propionate Chemical compound CCCCOC(=O)CC BTMVHUNTONAYDX-UHFFFAOYSA-N 0.000 description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 12
- 238000013459 approach Methods 0.000 description 11
- 230000007436 olfactory function Effects 0.000 description 10
- 239000011521 glass Substances 0.000 description 9
- 206010002653 Anosmia Diseases 0.000 description 8
- 238000013095 identification testing Methods 0.000 description 8
- 238000013461 design Methods 0.000 description 7
- LYRIITRHDCNUHV-UHFFFAOYSA-N ethyl 3-hydroxyhexanoate Chemical compound CCCC(O)CC(=O)OCC LYRIITRHDCNUHV-UHFFFAOYSA-N 0.000 description 7
- 238000010988 intraclass correlation coefficient Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000003044 adaptive effect Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000013351 cheese Nutrition 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 230000014860 sensory perception of taste Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 239000005662 Paraffin oil Substances 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 235000012432 gingerbread Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011870 unpaired t-test Methods 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101100521345 Mus musculus Prop1 gene Proteins 0.000 description 3
- 208000000592 Nasal Polyps Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108700017836 Prophet of Pit-1 Proteins 0.000 description 3
- 235000011941 Tilia x europaea Nutrition 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000004571 lime Substances 0.000 description 3
- 239000003973 paint Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 3
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 3
- 235000012141 vanillin Nutrition 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-β-pinene Chemical compound C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 2
- DPZNOMCNRMUKPS-UHFFFAOYSA-N 1,3-Dimethoxybenzene Chemical compound COC1=CC=CC(OC)=C1 DPZNOMCNRMUKPS-UHFFFAOYSA-N 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- PAPNRQCYSFBWDI-UHFFFAOYSA-N 2,5-Dimethyl-1H-pyrrole Chemical compound CC1=CC=C(C)N1 PAPNRQCYSFBWDI-UHFFFAOYSA-N 0.000 description 2
- LCZUOKDVTBMCMX-UHFFFAOYSA-N 2,5-Dimethylpyrazine Chemical compound CC1=CN=C(C)C=N1 LCZUOKDVTBMCMX-UHFFFAOYSA-N 0.000 description 2
- MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical compound CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 description 2
- LNIMMWYNSBZESE-UHFFFAOYSA-N 2-Ethyl-3-methylpyrazine, 9CI Chemical compound CCC1=NC=CN=C1C LNIMMWYNSBZESE-UHFFFAOYSA-N 0.000 description 2
- FZXRXKLUIMKDEL-UHFFFAOYSA-N 2-Methylpropyl propanoate Chemical compound CCC(=O)OCC(C)C FZXRXKLUIMKDEL-UHFFFAOYSA-N 0.000 description 2
- MBDOYVRWFFCFHM-UHFFFAOYSA-N 2-hexenal Chemical compound CCCC=CC=O MBDOYVRWFFCFHM-UHFFFAOYSA-N 0.000 description 2
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 2
- UXFSPRAGHGMRSQ-UHFFFAOYSA-N 3-isobutyl-2-methoxypyrazine Chemical compound COC1=NC=CN=C1CC(C)C UXFSPRAGHGMRSQ-UHFFFAOYSA-N 0.000 description 2
- XCZPDOCRSYZOBI-UHFFFAOYSA-N 5,6,7,8-Tetrahydroquinoxaline Chemical compound C1=CN=C2CCCCC2=N1 XCZPDOCRSYZOBI-UHFFFAOYSA-N 0.000 description 2
- CQLOYHZZZCWHSG-UHFFFAOYSA-N 5-methylquinoxaline Chemical compound C1=CN=C2C(C)=CC=CC2=N1 CQLOYHZZZCWHSG-UHFFFAOYSA-N 0.000 description 2
- LUYISICIYVKBTA-UHFFFAOYSA-N 6-methylquinoline Chemical compound N1=CC=CC2=CC(C)=CC=C21 LUYISICIYVKBTA-UHFFFAOYSA-N 0.000 description 2
- GHBSPIPJMLAMEP-UHFFFAOYSA-N 6-pentyloxan-2-one Chemical compound CCCCCC1CCCC(=O)O1 GHBSPIPJMLAMEP-UHFFFAOYSA-N 0.000 description 2
- SCCDQYPEOIRVGX-UHFFFAOYSA-N Acetyleugenol Chemical compound COC1=CC(CC=C)=CC=C1OC(C)=O SCCDQYPEOIRVGX-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 2
- 238000010989 Bland-Altman Methods 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 2
- 240000001238 Gaultheria procumbens Species 0.000 description 2
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- DMMJVMYCBULSIS-UHFFFAOYSA-N Methyl 3-(methylthio)propanoate Chemical compound COC(=O)CCSC DMMJVMYCBULSIS-UHFFFAOYSA-N 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010034018 Parosmia Diseases 0.000 description 2
- ZOZIRNMDEZKZHM-UHFFFAOYSA-N Phenethyl phenylacetate Chemical compound C=1C=CC=CC=1CCOC(=O)CC1=CC=CC=C1 ZOZIRNMDEZKZHM-UHFFFAOYSA-N 0.000 description 2
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 238000003643 Squared ranks test Methods 0.000 description 2
- 244000223014 Syzygium aromaticum Species 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 229960005233 cineole Drugs 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000017004 dementia pugilistica Diseases 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- ALVPFGSHPUPROW-UHFFFAOYSA-N dipropyl disulfide Chemical compound CCCSSCCC ALVPFGSHPUPROW-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- OMSUIQOIVADKIM-UHFFFAOYSA-N ethyl 3-hydroxybutyrate Chemical compound CCOC(=O)CC(C)O OMSUIQOIVADKIM-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- KVFIJIWMDBAGDP-UHFFFAOYSA-N ethylpyrazine Chemical compound CCC1=CN=CC=N1 KVFIJIWMDBAGDP-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- IFYYFLINQYPWGJ-UHFFFAOYSA-N gamma-decalactone Chemical compound CCCCCCC1CCC(=O)O1 IFYYFLINQYPWGJ-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- ZOCHHNOQQHDWHG-UHFFFAOYSA-N hexan-3-ol Chemical compound CCCC(O)CC ZOCHHNOQQHDWHG-UHFFFAOYSA-N 0.000 description 2
- AOGQPLXWSUTHQB-UHFFFAOYSA-N hexyl acetate Chemical compound CCCCCCOC(C)=O AOGQPLXWSUTHQB-UHFFFAOYSA-N 0.000 description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-N isocaproic acid Chemical compound CC(C)CCC(O)=O FGKJLKRYENPLQH-UHFFFAOYSA-N 0.000 description 2
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 2
- HJOVHMDZYOCNQW-UHFFFAOYSA-N isophorone Chemical compound CC1=CC(=O)CC(C)(C)C1 HJOVHMDZYOCNQW-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical compound CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- NUKZAGXMHTUAFE-UHFFFAOYSA-N methyl hexanoate Chemical compound CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 description 2
- IJXHLVMUNBOGRR-UHFFFAOYSA-N methyl nonanoate Chemical compound CCCCCCCCC(=O)OC IJXHLVMUNBOGRR-UHFFFAOYSA-N 0.000 description 2
- JGHZJRVDZXSNKQ-UHFFFAOYSA-N methyl octanoate Chemical compound CCCCCCCC(=O)OC JGHZJRVDZXSNKQ-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- GJQIMXVRFNLMTB-UHFFFAOYSA-N nonyl acetate Chemical compound CCCCCCCCCOC(C)=O GJQIMXVRFNLMTB-UHFFFAOYSA-N 0.000 description 2
- VSMOENVRRABVKN-UHFFFAOYSA-N oct-1-en-3-ol Chemical compound CCCCCC(O)C=C VSMOENVRRABVKN-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 2
- CFNJLPHOBMVMNS-UHFFFAOYSA-N pentyl butyrate Chemical compound CCCCCOC(=O)CCC CFNJLPHOBMVMNS-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- OSORMYZMWHVFOZ-UHFFFAOYSA-N phenethyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCCC1=CC=CC=C1 OSORMYZMWHVFOZ-UHFFFAOYSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 231100000133 toxic exposure Toxicity 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- KYWIYKKSMDLRDC-UHFFFAOYSA-N undecan-2-one Chemical compound CCCCCCCCCC(C)=O KYWIYKKSMDLRDC-UHFFFAOYSA-N 0.000 description 2
- KMPQYAYAQWNLME-UHFFFAOYSA-N undecanal Chemical compound CCCCCCCCCCC=O KMPQYAYAQWNLME-UHFFFAOYSA-N 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 229930006715 (-)-beta-pinene Natural products 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- HEVMDQBCAHEHDY-UHFFFAOYSA-N (Dimethoxymethyl)benzene Chemical compound COC(OC)C1=CC=CC=C1 HEVMDQBCAHEHDY-UHFFFAOYSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- NVIPUOMWGQAOIT-RQOWECAXSA-N (Z)-7-Hexadecen-1,16-olide Chemical compound O=C1CCCCC\C=C/CCCCCCCCO1 NVIPUOMWGQAOIT-RQOWECAXSA-N 0.000 description 1
- VSMOENVRRABVKN-MRVPVSSYSA-N 1-Octen-3-ol Natural products CCCCC[C@H](O)C=C VSMOENVRRABVKN-MRVPVSSYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- QEHNNAQSHBJMTJ-UHFFFAOYSA-N 2,2,3,3,4,4-hexamethyl-1h-naphthalene Chemical compound C1=CC=C2C(C)(C)C(C)(C)C(C)(C)CC2=C1 QEHNNAQSHBJMTJ-UHFFFAOYSA-N 0.000 description 1
- KYUNECWPKRYPJM-UHFFFAOYSA-N 2,2-dimethyl-3-phenylpropanal Chemical compound O=CC(C)(C)CC1=CC=CC=C1 KYUNECWPKRYPJM-UHFFFAOYSA-N 0.000 description 1
- GZXXANJCCWGCSV-UHFFFAOYSA-N 2,3-Diethylpyrazine Chemical compound CCC1=NC=CN=C1CC GZXXANJCCWGCSV-UHFFFAOYSA-N 0.000 description 1
- 239000001934 2,5-dimethylpyrazine Substances 0.000 description 1
- RMFCMEVNMFHDSL-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)ethanimidamide Chemical compound NC(=N)CC1=CC=C(Cl)C(Cl)=C1 RMFCMEVNMFHDSL-UHFFFAOYSA-N 0.000 description 1
- ZSDQQJHSRVEGTJ-UHFFFAOYSA-N 2-(6-amino-1h-indol-3-yl)acetonitrile Chemical compound NC1=CC=C2C(CC#N)=CNC2=C1 ZSDQQJHSRVEGTJ-UHFFFAOYSA-N 0.000 description 1
- AJKVQEKCUACUMD-UHFFFAOYSA-N 2-Acetylpyridine Chemical compound CC(=O)C1=CC=CC=N1 AJKVQEKCUACUMD-UHFFFAOYSA-N 0.000 description 1
- MBDOYVRWFFCFHM-SNAWJCMRSA-N 2-Hexenal Natural products CCC\C=C\C=O MBDOYVRWFFCFHM-SNAWJCMRSA-N 0.000 description 1
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N 2-Methylheptane Chemical compound CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- RJASFPFZACBKBE-UHFFFAOYSA-N 2-Methylpropyl phenylacetate Chemical compound CC(C)COC(=O)CC1=CC=CC=C1 RJASFPFZACBKBE-UHFFFAOYSA-N 0.000 description 1
- HMKKIXGYKWDQSV-SDNWHVSQSA-N 2-Pentyl-3-phenyl-2-propenal Chemical compound CCCCC\C(C=O)=C/C1=CC=CC=C1 HMKKIXGYKWDQSV-SDNWHVSQSA-N 0.000 description 1
- HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 description 1
- QGLVWTFUWVTDEQ-UHFFFAOYSA-N 2-chloro-3-methoxyphenol Chemical compound COC1=CC=CC(O)=C1Cl QGLVWTFUWVTDEQ-UHFFFAOYSA-N 0.000 description 1
- WOYWLLHHWAMFCB-UHFFFAOYSA-N 2-ethylhexyl acetate Chemical compound CCCCC(CC)COC(C)=O WOYWLLHHWAMFCB-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- YDXQPTHHAPCTPP-UHFFFAOYSA-N 3-Octen-1-ol Natural products CCCCC=CCCO YDXQPTHHAPCTPP-UHFFFAOYSA-N 0.000 description 1
- RPBPHGSYVPJXKT-UHFFFAOYSA-N 3-bromo-2-phenylmethoxypyridine Chemical compound BrC1=CC=CN=C1OCC1=CC=CC=C1 RPBPHGSYVPJXKT-UHFFFAOYSA-N 0.000 description 1
- ZOQDGMRYMRFKRV-UHFFFAOYSA-N 3-methyl-2,1-benzoxazole Chemical compound C1=CC=CC2=C(C)ON=C21 ZOQDGMRYMRFKRV-UHFFFAOYSA-N 0.000 description 1
- UJTKZWNRUPTHSB-UHFFFAOYSA-N 4-(4-bromophenyl)morpholine Chemical compound C1=CC(Br)=CC=C1N1CCOCC1 UJTKZWNRUPTHSB-UHFFFAOYSA-N 0.000 description 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 1
- HFNGYHHRRMSKEU-UHFFFAOYSA-N 4-Methoxybenzyl acetate Chemical compound COC1=CC=C(COC(C)=O)C=C1 HFNGYHHRRMSKEU-UHFFFAOYSA-N 0.000 description 1
- JRHHJNMASOIRDS-UHFFFAOYSA-N 4-ethoxybenzaldehyde Chemical compound CCOC1=CC=C(C=O)C=C1 JRHHJNMASOIRDS-UHFFFAOYSA-N 0.000 description 1
- LEGGANXCVQPIAI-UHFFFAOYSA-N 4-methyl-octanoic acid Chemical compound CCCCC(C)CCC(O)=O LEGGANXCVQPIAI-UHFFFAOYSA-N 0.000 description 1
- DPZMVZIQRMVBBW-UHFFFAOYSA-N 5-Phenyl-1-pentanol Chemical compound OCCCCCC1=CC=CC=C1 DPZMVZIQRMVBBW-UHFFFAOYSA-N 0.000 description 1
- VNFYMAPAENTMMO-UHFFFAOYSA-N 5-chloro-2-methylquinoline Chemical compound ClC1=CC=CC2=NC(C)=CC=C21 VNFYMAPAENTMMO-UHFFFAOYSA-N 0.000 description 1
- QUAMMXIRDIIGDJ-UHFFFAOYSA-N 5-ethenyl-4-methyl-1,3-thiazole Chemical compound CC=1N=CSC=1C=C QUAMMXIRDIIGDJ-UHFFFAOYSA-N 0.000 description 1
- 239000001640 5-methylquinoxaline Substances 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- TWXUTZNBHUWMKJ-UHFFFAOYSA-N Allyl cyclohexylpropionate Chemical compound C=CCOC(=O)CCC1CCCCC1 TWXUTZNBHUWMKJ-UHFFFAOYSA-N 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- LDOXTQYWWYXYSQ-UHFFFAOYSA-N Butyl phenylacetate Chemical compound CCCCOC(=O)CC1=CC=CC=C1 LDOXTQYWWYXYSQ-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- RZTOWFMDBDPERY-UHFFFAOYSA-N Delta-Hexanolactone Chemical compound CC1CCCC(=O)O1 RZTOWFMDBDPERY-UHFFFAOYSA-N 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- KBEBGUQPQBELIU-CMDGGOBGSA-N Ethyl cinnamate Chemical compound CCOC(=O)\C=C\C1=CC=CC=C1 KBEBGUQPQBELIU-CMDGGOBGSA-N 0.000 description 1
- ICMAFTSLXCXHRK-UHFFFAOYSA-N Ethyl pentanoate Chemical compound CCCCC(=O)OCC ICMAFTSLXCXHRK-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010050515 Hyposmia Diseases 0.000 description 1
- VHVOLFRBFDOUSH-NSCUHMNNSA-N Isosafrole Chemical compound C\C=C\C1=CC=C2OCOC2=C1 VHVOLFRBFDOUSH-NSCUHMNNSA-N 0.000 description 1
- VHVOLFRBFDOUSH-UHFFFAOYSA-N Isosafrole Natural products CC=CC1=CC=C2OCOC2=C1 VHVOLFRBFDOUSH-UHFFFAOYSA-N 0.000 description 1
- JGFBQFKZKSSODQ-UHFFFAOYSA-N Isothiocyanatocyclopropane Chemical compound S=C=NC1CC1 JGFBQFKZKSSODQ-UHFFFAOYSA-N 0.000 description 1
- VYQSSWZYPCCBRN-UHFFFAOYSA-N Isovaleriansaeure-menthylester Natural products CC(C)CC(=O)OC1CC(C)CCC1C(C)C VYQSSWZYPCCBRN-UHFFFAOYSA-N 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 201000007493 Kallmann syndrome Diseases 0.000 description 1
- 208000003892 Kartagener syndrome Diseases 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- WKSXRWSOSLGSTN-UHFFFAOYSA-N Methoxypyrazine Chemical compound COC1=CN=CC=N1 WKSXRWSOSLGSTN-UHFFFAOYSA-N 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 206010053142 Olfacto genital dysplasia Diseases 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- LQKRYVGRPXFFAV-UHFFFAOYSA-N Phenylmethylglycidic ester Chemical compound CCOC(=O)C1OC1(C)C1=CC=CC=C1 LQKRYVGRPXFFAV-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- GRLJIIJNZJVMGP-UHFFFAOYSA-N S-Methyl butanethioate Chemical compound CCCC(=O)SC GRLJIIJNZJVMGP-UHFFFAOYSA-N 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 208000028347 Sinus disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- AAQDYYFAFXGBFZ-UHFFFAOYSA-N Tetrahydrofurfuryl acetate Chemical compound CC(=O)OCC1CCCO1 AAQDYYFAFXGBFZ-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000001850 [(2R)-oxolan-2-yl]methyl acetate Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- ZCZSIDMEHXZRLG-UHFFFAOYSA-N acetic acid heptyl ester Natural products CCCCCCCOC(C)=O ZCZSIDMEHXZRLG-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229940008075 allyl sulfide Drugs 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 235000019558 anosmia Nutrition 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 229940115397 bornyl acetate Drugs 0.000 description 1
- 235000010634 bubble gum Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- XAPCMTMQBXLDBB-UHFFFAOYSA-N butanoic acid hexyl ester Natural products CCCCCCOC(=O)CCC XAPCMTMQBXLDBB-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- PWLNAUNEAKQYLH-UHFFFAOYSA-N butyric acid octyl ester Natural products CCCCCCCCOC(=O)CCC PWLNAUNEAKQYLH-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- KBEBGUQPQBELIU-UHFFFAOYSA-N cinnamic acid ethyl ester Natural products CCOC(=O)C=CC1=CC=CC=C1 KBEBGUQPQBELIU-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004883 computer application Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- SKQYTJLYRIFFCO-UHFFFAOYSA-N delta-Tetradecalactone Chemical compound CCCCCCCCCC1CCCC(=O)O1 SKQYTJLYRIFFCO-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- VKNUORWMCINMRB-UHFFFAOYSA-N diethyl malate Chemical compound CCOC(=O)CC(O)C(=O)OCC VKNUORWMCINMRB-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000032099 esthesioneuroblastoma Diseases 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000020803 food preference Nutrition 0.000 description 1
- IFYYFLINQYPWGJ-VIFPVBQESA-N gamma-Decalactone Natural products CCCCCC[C@H]1CCC(=O)O1 IFYYFLINQYPWGJ-VIFPVBQESA-N 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- JPXGPRBLTIYFQG-UHFFFAOYSA-N heptan-4-yl acetate Chemical compound CCCC(CCC)OC(C)=O JPXGPRBLTIYFQG-UHFFFAOYSA-N 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 235000019559 hyposmia Nutrition 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
- 208000014548 isolated congenital anosmia Diseases 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- DILOFCBIBDMHAY-UHFFFAOYSA-N methyl 2-(3,4-dimethoxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(OC)C(OC)=C1 DILOFCBIBDMHAY-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- NTLJTUMJJWVCTL-UHFFFAOYSA-N methyl non-2-ynoate Chemical compound CCCCCCC#CC(=O)OC NTLJTUMJJWVCTL-UHFFFAOYSA-N 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000010705 motor oil Substances 0.000 description 1
- UUIQMZJEGPQKFD-UHFFFAOYSA-N n-butyric acid methyl ester Natural products CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 description 1
- HNBDRPTVWVGKBR-UHFFFAOYSA-N n-pentanoic acid methyl ester Natural products CCCCC(=O)OC HNBDRPTVWVGKBR-UHFFFAOYSA-N 0.000 description 1
- 239000003345 natural gas Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- BTFQKIATRPGRBS-UHFFFAOYSA-N o-tolualdehyde Chemical compound CC1=CC=CC=C1C=O BTFQKIATRPGRBS-UHFFFAOYSA-N 0.000 description 1
- FUBGRVHGQADOJI-UHFFFAOYSA-N octyl 3-methyl-butanoate Chemical compound CCCCCCCCOC(=O)CC(C)C FUBGRVHGQADOJI-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 201000010444 olfactory groove meningioma Diseases 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 235000019546 parosmia Nutrition 0.000 description 1
- HVAMZGADVCBITI-UHFFFAOYSA-N pent-4-enoic acid Chemical compound OC(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019554 phantosmia Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940098888 phenethyl benzoate Drugs 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000009266 primary ciliary dyskinesia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 235000019561 smell disorders Nutrition 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- MHRKPCRXBAHJGS-OAHLLOKOSA-N tert-butyl n-[[(3r)-1-benzylpyrrolidin-3-yl]methyl]carbamate Chemical compound C1[C@@H](CNC(=O)OC(C)(C)C)CCN1CC1=CC=CC=C1 MHRKPCRXBAHJGS-OAHLLOKOSA-N 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4005—Detecting, measuring or recording for evaluating the nervous system for evaluating the sensory system
- A61B5/4011—Evaluating olfaction, i.e. sense of smell
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
Definitions
- the disclosure generally relates to compositions and methods of sensory diagnosis and/or repair.
- Smell dysfunction manifests itself primarily in the reduced ability to detect or identify volatile chemicals, and ranges from the complete inability to smell any odors, to a partial reduction in olfactory sensitivity, to smell distortion, for instance that a large number of odors smell like cigarette smoke.
- the prevalence of smell dysfunction in the general adult population is about 20% in Europe and the United States (1-3). This condition is dangerous because those affected are unable to detect fire, spoiled food, hazardous chemicals, and leaks of odorized natural gas (4, 5).
- Smell loss also has severe health consequences, including mental health symptoms such as depression, anxiety, and social isolation. It affects quality of life by altering food preferences and the amount of food ingested (5). Food is often perceived as bland or tasteless by patients with smell disorders, leading to loss of appetite or overeating (4, 5).
- Smell dysfunction has many causes, including head trauma, upper respiratory tract infection, nasal polyps, and congenital anomalies (6, 7). In many cases, the cause of smell dysfunction is unknown (5, 8). Importantly, smell dysfunction is an early sign of Alzheimer's disease (9), the most common cause of dementia in the United States that is projected to affect an estimated 1 in every 45 individuals by 2050 (10). There is growing evidence that diminished olfactory function arises early in the progression of Alzheimer's disease, and is highly predictive of future cognitive decline (3, 4). Because of the high prevalence and dramatic consequences of smell loss, accurate diagnosis of olfactory dysfunction is important. While self-reported hearing loss tends to be accurate (11), self-reporting of olfactory dysfunction is notoriously unreliable. Therefore, accurate diagnostic tests for smell dysfunction that can be deployed worldwide are critically important. Following a diagnosis, therapeutic options and counseling can be offered to patients suffering from smell loss (12).
- odor stimuli In clinical smell testing, patients are presented with odor stimuli in a variety of formats, including scratch ‘n’ sniff strips, glass vials or jars, felt-tip pens, or paper scent strips used in perfume shops, and asked to answer questions about what they smell. Smell tests assess the ability of subjects to detect, discriminate, or identify odors. Olfactory threshold tests measure the lowest concentration of an odor stimulus that a patient can perceive, while discrimination tests assess the ability of subjects to distinguish two different smells. Finally, odor identification tests evaluate whether a patient can detect and match odors to standard words that describe the smell (13).
- the second challenge is to develop a test that is not influenced by the patient's prior olfactory experiences.
- This has an obvious influence on the results of odor identification tests such as the University of Pennsylvania Smell Identification Test (UPSIT) for which subjects are given a booklet with 40 scratch ‘n’ sniff items and asked to select one of four words (for example “gingerbread”, “menthol”, “apple”, or “cheddar cheese”) that best describes what the odor smells like.
- UPSIT University of Pennsylvania Smell Identification Test
- Whether a patient can correctly identify the smell of gingerbread depends not only on the patient's sense of smell, but also on whether the patient has previously encountered the smell of gingerbread. This in turn depends on many factors such as the cultural and age group the patient belongs to.
- the UPSIT has been adapted for use in a number of countries worldwide by replacing unfamiliar items and adapting the answers on the multiple-choice test.
- the North American UPSIT was adapted for Taiwanese subjects by replacing “clove”, “cheddar cheese”, “cinnamon”, “gingerbread”, “dill pickle”, “lime”, “wintergreen”, and “grass” with “sandalwood”, “fish”, “coffee”, “rubber tire”, “jasmine”, “grapefruit”, “magnolia”, and “baby powder” (18).
- the strong influence of prior olfactory experience on the test results limits the utility of odor identification tests.
- the present disclosure provides compositions, kits, and methods for determining olfactory sensitivity and olfactory resolution.
- the disclosure provides distinct ensembles of odorants that can be used in making such determinations.
- odorants are provided in a plurality of dilutions, such as serial dilutions, such that iterative exposure to the distinct dilutions provides for quantifying and/or scoring olfactory sensitivity and/or resolution.
- the lowest concentration of an odor stimulus that a subject can perceive is determined, and used to provide a value for olfactory sensitivity.
- a subject's capacity to distinguish distinct smells from one another is quantified and/or scored to provide a value for olfactory resolution.
- Certain aspects of olfactory resolution and/or sensitivity can be assessed using a variety of experimental designs, a non-limiting example of which comprises a triangle test, whereby the capacity of an individual to determine the presence or absence of an olfactory stimulus, and/or to discriminate between distinct olfactory stimuli, is analyzed.
- a value determined using an approach described herein can be used to assist in a diagnosis of an olfactory defect, and/or another condition or disorder that is correlated with olfactory sensory acuity, for example, by determining a sensitivity and/or resolution value that is lower or different from a threshold or reference value.
- methods of the disclosure can comprise performance of triangle tests.
- Triangle tests are known to those skilled in the art as a discriminative approach used in sensory science to determine the presence or absence of a stimulus, and/or a difference between distinct samples, such as by asking a subject to select one of three stimuli that is different from the other two.
- Kits comprising combinations of odorants described herein are also provided.
- FIG. 1 shows SMELL-S olfactory sensitivity and SMELL-R olfactory resolution tests.
- A Schematic of triangle test stimuli for SMELL-S, comprising two glass vials containing solvent (gray) and one containing increasingly diluted mixtures of 30 molecules (red-white mosaic). Olfactory sensitivity of a subject measured with SMELL-S [Subject Expt 1-A023, SMELL-S (v2)].
- FIG. 2 shows test-retest reliability and relationship between SMELL-S and SMELL-R tests.
- A Experiment 1 design, showing one example of the many different presentations of the six smell tests. SMELL-R tests were always administered after SMELL-S or threshold tests in a given visit.
- FIG. 3 shows addressing the problem of odor-specific insensitivity.
- B Experiment 2 design.
- C The relationship between different etiologies of olfactory dysfunction and UPSIT scores in published studies, as well as of Experiment 2 subjects divided by self-reported smell abilities (mean ⁇ 95% confidence interval).
- FIG. 4 shows SMELL-S and SMELL-R diagnostic accuracy.
- B Area under the ROC curve (AUC) for SMELL-S (v2). The optimal cut-off is indicated by the blue dot.
- C Plots of four measures of diagnostic accuracy resulting from different cut-off scores for SMELL-S (v2) (percentage ⁇ 95% confidence interval).
- E Area under the ROC curve (AUC) for SMELL-R (v2).
- the optimal cut-off is indicated by the green dot.
- F Plots of four measures of diagnostic accuracy resulting from different cut-off scores for SMELL-R (v2) (rate or percentage ⁇ 95% confidence interval).
- the optimal cut-off score for olfactory dysfunction defined by Youden's Index (center) is indicated by the green dot. Subjects with identical values are indicated by superimposed open circles and an X, and retain the specified color coding.
- FIG. 5 shows addressing the problem of different prior olfactory experiences.
- A Experiment 3 design.
- C-D Histogram of North American and Taiwanese subject scores for the UPSIT (C) and SMELL-R (v2) (D).
- E Cross-population comparison of UPSIT and SMELL-R (v2) (mean ⁇ 95% confidence interval) for subjects in (C,D).
- FIG. 6 shows SMELL-S (panel A) and SMELL-R (panel B) stimuli are stable over 4 months of testing.
- the median and interquartile range of testing score per study visit day were plotted. The slope of the data was fitted by linear regression, and analyzed for significant difference from a slope of zero, which would correspond to perfect stability across the testing period. Stimuli for each test were freshly made only once at the beginning of the study, stored at room temperature in a ventilated lab, and used throughout the study. Study visit days took place 2-3 times a week. We tested 75 subjects who performed each one of the 4 tests twice.
- the disclosure includes all method steps and compositions of matter described herein in the text figures and tables of this disclosure, including all such steps individually and in all combinations thereof.
- the disclosure includes all compositions of matter including but not necessarily limited to every combination and sub-combination of compounds described herein, all dilutions of the compounds, all compound mixtures, all compound ratios, and all combinations of compound combinations that may be provided in single containers, or more than one container, and sets of compounds provided in single and separate containers.
- Containers are defined as the vehicle by which stimuli are presented to the subject, and can comprise a solid or liquid formulation in a vial or jar; a scratch ‘n’ sniff scent strip; a solid or liquid formulation in a device that produces a vapor or aerosol of the stimuli.
- the stimuli can be delivered manually by the subjects manipulating the container and sniffing, or digitally by a device that automatically delivers the stimuli to the subject.
- a mixture of compounds described herein can be provided in a semi-solid composition, including but not limited to a wax.
- mixtures that are present in, for example, a wax can be provided as a component of a device, such as a disk, or cartridge.
- the disclosure includes a system comprising one or more disks or cartridges that comprise a mixture of compounds described herein in a liquid, semi-solid, or solid medium.
- the system allows for production and/or dissemination to a user of a vapor, such as in the presence of a drift, such as an air drift.
- the compound combinations can comprise or consist of any of the compounds listed for any combination thereof, and my further include buffers or diluents that, for example, do not impact the olfactory system of a subject undergoing testing using the compounds.
- the disclosure includes a proviso that any compound or combination of compounds can be excluded from the claims of this application or patent, including but not necessarily limited to those compounds disclosed herein as “excluded” wherein the exclusion is for any reason, including but not limited to lateralization score or intensity-matching, or a combination thereof.
- Compounds of this disclosure are provided with compound identifiers (CID) which are the permanent identifier for a unique chemical structure as curated in PubChem, a project of the National Center for Biotechnology Information (NCBI) of the US government.
- CID compound identifiers
- compositions comprising any combination of compounds described herein remain stable over a period of time, such as from seven days, to at least a period of twelve months, including all days and intervals of days there between.
- the combinations of compounds are stored at room temperature and remain stable.
- stability is determined by the combination of compounds remaining suitable for using in a method described herein. In an embodiment, stability is determined as described for FIG. 6 , which demonstrates determining stability of SMELL-S ( FIG. 6 , panel A) and SMELL-R ( FIG.
- the disclosure includes measuring olfactory sensitivity, olfactory resolution, and combinations thereof. Such measurements can be made during a single test, or over consecutive tests, which may be performed during a single testing period, such as in a single day, or over a series of testing periods.
- the tests may be performed by a health care professional, or may be conveniently self-administered by the user.
- the tests thus involve methods for evaluating the olfactory function of an individual.
- the methods generally comprise allowing a subject to nasally inhale odorants from any combination of compounds and/or series of compound combinations described herein such that a determination of the sensitivity and/or the resolution capability of the olfactory function of the individual is made.
- the disclosure includes assigning threshold and/or score values to the olfactory function of the individual, as further described herein.
- the disclosure includes using the compound combinations described herein to assess olfactory function and generate one or more scores or other values that represent olfactory sensitivity, olfactory resolution, and/or combinations thereof.
- the disclosure includes use of control combinations of compounds and comparing perception of smell of test combinations to perception of smell to the control combinations.
- the disclosures provides for integration of the testing procedures described herein with adaptive software to develop one or more thresholds and/or scores for olfactory sensitivity and/or resolution.
- embodiments of the disclosure can in part be implemented by a device comprising a microprocessor running software to perform one or more calculations described herein.
- the disclosure includes an application (i.e., an app) that can guide a user through one or a series of tests described herein, and whereby the test results can be entered into the app and one or more threshold values or scores can be generated and presented to the user via a user interface.
- Such apps can be configured to run on a computer connected to a bar code scanner, or any mobile device, such as a mobile phone or a tablet that can scan a QR code with a camera.
- the software/app interfaces with a scent delivery device that controls the release of the stimuli, wherein the stimuli comprise a combination of compounds as described herein.
- the disclosure comprises a distributed system in a networked environment.
- the invention facilitates determination of the lowest concentration of an odor stimulus that a subject can perceive, and thus provides for generating a value for olfactory sensitivity.
- the invention facilitates analysis of a subject's ability to distinguish distinct smells from one another, and thus provides a value for olfactory resolution.
- methods of the disclosure can comprise performance of triangle tests. Triangle tests are known to those skilled in the art as a discriminative approach used in sensory science to determine the presence or absence of a stimulus, and/or a difference between distinct samples, such as by asking a subject to select one of three stimuli that is different from the other two.
- subjects are tested using a series of odorant combinations, which may or may not be presented using a triangle test approach, to determine which of a series of test combinations of odorants can be perceived using, for instance, serial dilutions of combinations of odorants, until a threshold is reached wherein no smell can be perceived.
- subjects are tested to determine which of a series of test combinations of odorants are different from a reference combination, such as by removal or replacement of one or more odorants from a series of odorant combinations, until a threshold is reached, wherein difference in smell between a sample and a reference cannot be detected.
- a triangle test may comprise a test using three unknown samples to determine whether or not an individual can determine which sample is distinct from the others, i.e., the individual is provided samples XXY, which represents three compounds or combinations of compounds or dilutions thereof, to the individual, and the individual is tested to determine whether or not the individual can identify Y as distinct from samples XX.
- Non-limiting embodiments of the disclosure are generally outlined in FIG. 1 , wherein panel A in FIG. 1 depicts an approach to determining olfactory sensitivity, and wherein FIG. 1 , panel B, presents an approach to determining olfactory resolution. All steps and combinations of steps depicted in the figures of this disclosure are included within its scope. All dilution values described herein, whether or not depicted in the figures, are encompassed within this disclosure. All possible combinations of compounds listed Supporting Data Set 1 and all other tables provided herein are encompassed by this disclosure. Any single compound, or any combination of compounds described herein, can be excluded from the claims.
- the disclosure provides for determining a threshold score that is at least in part calculated using a reversal, wherein a reversal comprises a change in the direction of the concentration used for the test, i.e., the subject who is nasally inhaling samples with increasing concentrations is subsequently provided a decreased concentration, or vice versa.
- a reversal comprises a change in the direction of the concentration used for the test, i.e., the subject who is nasally inhaling samples with increasing concentrations is subsequently provided a decreased concentration, or vice versa.
- more than one reversal point can be attained in order to determine a threshold value.
- from 1-7 reversals are attained.
- a threshold value is determined when a subject cannot detect a particular high concentration of odorants at least twice, or the subject detects a particular low concentration of odorants more than one time.
- a threshold value can be the same as, or used in establishing a score for the individual.
- a score can be determined using reversals in combination with concentration values where one, or a series, or an average of concentration values where reversal(s) occurred are used.
- an individual is assigned a score of from 1-16, wherein 16 indicates the individual is able to correctly identify low concentrations of odorants, whereas a score of 1 indicates the individual was not able to identify high concentrations of odorants.
- Such thresholds and scores can be used for determining olfactory sensitivity, and can be adapted for determining olfactory resolution.
- standard staircase procedures can be used, given the benefit of the present disclosure, to determine a subject's ability to discriminate between different combinations of compounds that can be, for example, altered in a stepwise fashion to become increasingly similar or dissimilar to each other, and/or to test the capability of an individual to detect a sample that is dissimilar from other sample(s), such as is generally outlined in FIG. 1B .
- compositions, kits and methods of this disclosure are broadly applicable to geographically and culturally distinct populations of human individuals, and to individuals over a variety of ages.
- the disclosure removes difficulties of, for example, semantic-based smell tests that include biases based on lack of prior exposure to an odorant, and/or an inability to verbalize a characteristic of an odorant due to geographical, cultural, or linguistic influences or experience.
- the present disclosure provides smell tests that use mixtures of molecules that average out the variability in sensitivity to individual molecules. Because these mixtures have unfamiliar odors, and the tests are non-semantic, their use eliminates differences in test performance due to the familiarity with the smells or the words used to describe them.
- the tests facilitate smell testing of diverse populations, without the need to adapt the test stimuli.
- compositions and methods of this disclosure are used to test a human individual who is diagnosed with, suspected of having, or is at risk for developing one or more sensory and/or cognitive disorders.
- the individual is at risk for developing a cognitive disorder that comprises memory loss, and/or dementia.
- the disclosure is used to aid in diagnosis of such a disorder, and may moreover contribute to earlier diagnosis than has been possible before the development of the present invention.
- the disorder is Alzheimer's disease, or is a post-concussion syndrome, or Chronic Traumatic Encephalopathy (CTE).
- CTE Chronic Traumatic Encephalopathy
- the disclosure aids in diagnosis of hyposmia, anosmia, parosmia, or phantosmia.
- compositions and methods of this disclosure may assist in the diagnosis of include but are not necessarily limited to: inflammatory nasal and sinus diseases, such as those caused by postviral olfactory dysfunction, chronic rhinosinusitis with nasal polyps, chronic rhinosinusitis without nasal polyps; nasal tumors, including esthesioneuroblastoma, adenocarcinoma, respiratory epithelial adenomatoid hamartoma; neurodegenerative diseases including Parkinson's Disease and Huntington's Disease; normal aging; toxic exposure to chemicals in the industrial workplace; congenital syndromes affecting the sense of smell, including Kallmann Syndrome, Kartagener Syndrome, Isolated Congenital Anosmia; brain tumors, including olfactory groove meningioma or temporal lobe neoplasia; systemic diseases, including diabetes, alcoholism, liver failure, renal failure, hypothyroidism, systemic lupus erythematosus; and psychiatric disorders,
- compositions and methods of this disclosure can aid in monitoring a treatment for one or more conditions.
- an individual can be evaluated with an initial test or set of tests described herein to establish baseline values for olfactory sensitivity and/or olfactory resolution.
- the individual can subsequently be re-tested after, for example, a period of therapy for a disorder, and if the individual exhibits an improvement in a value for olfactory sensitivity and/or olfactory resolution relative to the baseline it may be indicative that the particular therapy is effective.
- the individual exhibits worsening of a value for olfactory sensitivity and/or olfactory resolution relative to the baseline it may be indicative that the particular therapy is not effective.
- Similar approaches can be adapted to determine if, for example, a particular agent, such as pharmaceutical agent or environmental agent, is having an impact on the olfactory function of an individual.
- the disclosure is suitable for evaluating whether an individual has suitable olfactory properties that relate to, for example, a particular occupation wherein sense of smell is important for safety or other reasons, including but not necessarily limited to the development of consumer and industrial products that produce or otherwise involve perception of distinct odors.
- SMELL-S olfactory sensitivity
- SMELL-R olfactory resolution
- SMELL-R showed significantly less bias in scores between North American and Taiwanese subjects than conventional semantically-based smell tests that need to be adapted and translated to different populations. It is expected that SMELL-S and SMELL-R will be broadly effective in diagnosing smell dysfunction, including that associated with the earliest signs of memory loss in Alzheimer's disease.
- compounds used during testing according to this disclosure are provided to the subject in identical containers, with the proviso that coded indicia signifying to the test provider may be included to identify the composition of the compounds.
- at least two containers, or at least three containers are provided. At least one of the containers comprises a distinct combination of compounds, and/or a distinct dilution of compounds, relative to at least one other container.
- the containers are arranged in a particular order, such as a line, and the subject nasally inhales the sample from left to right, or right to left, or top to bottom, or bottom to top, etc.
- the subject identifies strongest odor (SMELL-S, as described below) or the odd odor (SMELL-R, as described below), or completes both tests.
- the disclosure provides combinations of the following compounds, which are also listed in the “Molecules Included” table that is part of the Supporting Data Set 1 that forms a part of this disclosure: butyraldehyde, cuminaldehyde, octanal, dihydrocoumarin, octanol, phenethylamine, pyruvic acid, methyl sulfide, 4-methyl-5-thiazoleethanol, decanoic acid, eugenol, 2-phenylethanol, dimethyl anthranilate, 2-isopropylphenol, 2-methoxy-4-methylphenol, carvyl acetate, furfuryl alcohol, ⁇ -methylbenzyl alcohol, acetophenone, methyl phenylacetate, diphenyl ether, ⁇ , ⁇ -dimethylbenzenepropanol, phenethyl acetate, 2-ethyl-1-hexanol, 4-methylanisole, ethyl propionate
- the disclosure includes combinations of that comprise or consist of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 of these compounds. Mixtures that include more than 30 compounds, whether or not they are the compounds described herein, are also included. In embodiments, the disclosure comprises combinations of these compounds, wherein the compounds are divided into more than one container. Any container suitable for holding the compounds, and whereby a human subject can access the container to smell its contents, is included in the disclosures. In embodiments, the container comprises a glass or plastic vessel which may comprise an attached or removal cover or cap.
- the vessel is ajar, a tube, or a vial.
- the vessel comprises an absorbent material.
- the vessel comprises a digital scent delivery device that volatilizes or aerosolizes the stimuli from a solid or liquid form.
- the disclosure comprises combinations that contain all of compounds in the Molecules Included list below, wherein sets of the compounds, such as from 2-30 of the compounds, are divided into separate containers.
- the disclosures comprises sets of these compounds, wherein the compounds are diluted by a method and in a solvent appropriate for a given delivery system such as one or more dilutions obtained from a serial dilution.
- the disclosure comprises any combination(s) or sets of combinations of compounds that are described in the “Table SMELL-R and SMELL-S Combinations” table that is part of the Supporting Data Set 1.
- one or more of the compounds are diluted as set forth in the SMELL-R and SMELL-S Combinations table.
- kits can comprise one or more containers comprising any combination of compounds described herein, and may comprise empty containers for iterative tests, and/or for making compound dilutions for use in the methods described herein.
- the kits can include one or more solutions, such as for dissolving or suspending or dispersing any of the compounds described herein, and/or for diluting such compounds.
- the kits may comprise compound master mixes that are suitable for use directly, or for making dilutions and compound combinations as described herein.
- the kits can include printed material or a means for accessing web-hosted information that instructs the user how to perform the sensitivity and/or resolution tests described herein.
- the disclosure comprises fixing one or more results from a test described herein in a tangible medium of expression, and optionally communicating the test result to a database, and/or to a health care provider.
- This example provides a description of smell tests: SMELL-S and SMELL-R.
- the Olfactory Sensitivity Test measures sensitivity to a mixture of 30 monomolecular odorants ( FIG. 1A ).
- the Olfactory Resolution Test (SMELL-R) measures the ability of subjects to discriminate the smell of such mixtures with an increase in overlapping components ( FIG. 1B ) (21, 22). Tests were presented in glass jars or vials as triangle tests, in which subjects were asked to pick out the stimulus with the strongest odor (SMELL-S) or the odd odor (SMELL-R). Both tests used adaptive staircase procedures that are standard in clinical olfactory testing ( FIG.
- test-retest reliability for SMELL-S
- the bias as defined by the difference between the average of the test and retest scores, was close to zero for all three tests. This indicates that subjects did not show systematically different performance between the test and retest sessions.
- the 95% limits of agreement were much smaller for the two SMELL-S tests than the phenylethyl alcohol threshold test ( FIG. 2B ).
- the phenylethyl alcohol threshold test is commercially available as Sniffin' Sticks, a well-validated test administered by clinical staff that utilizes felt-tip pens for odorant delivery (23, 25).
- Sniffin' Sticks a well-validated test administered by clinical staff that utilizes felt-tip pens for odorant delivery (23, 25).
- SMELL-S v2
- the standard measure of clinical test accuracy is the area under the receiver operating characteristic (ROC) curve, which plots the true and false positive rates at different cut-off scores.
- the area under the ROC curve of SMELL-S (v2) is 0.98 (95% confidence interval: 0.85-1.00) ( FIG. 4B ), which is close to the perfect accuracy of 1.
- An aspect of this disclosure is the development of a test that does not have to be adapted to different populations.
- SMELL-R (v2) performs well in different countries
- SMELL-R (v2) performance between Taiwanese and North American subjects Example 3, FIG. 5A .
- As a positive control we used the North American version of the UPSIT for both populations, because previous work has shown that Taiwanese subjects have systematically lower scores on this test due to unfamiliarity with several of the test items (18).
- Taiwanese subjects had a Chinese translation of the English multiple-choice questions in the test booklet.
- SMELL-R (v2) did not require any language translation because it is non-semantic.
- Taiwanese subjects scored higher on SMELL-R (v2) than the North American subjects ( FIG. 5D ) (p 0.0157, Mann Whitney test).
- SMELL-R (v2) can be applied across different populations with different prior olfactory experiences, and without the need to adapt it to the local culture and language.
- Subjects were aged 18 or over and agreed to refrain from using perfume or cologne, and ingesting anything except water one hour prior to the study visit. At the beginning of each visit, subjects washed their hands with odorless soap. For subjects reporting a normal sense of smell and taste, we excluded subjects who presented with current or past history of conditions that might be related to smell loss (acute or chronic rhinosinusitis, nasal tumor, upper respiratory tract infection or head trauma that altered the sense of smell for more than one month, history of brain or sinonasal surgery, asthma, stroke, neurodegenerative disease, radiation therapy or chemotherapy, active smoking, or consumption of medication affecting the sense of smell during the study). Participants with self-reported smell dysfunction were not subject to these exclusion criteria. All raw data in the paper, including details about the demographics of the subjects, odorants, and composition of the test stimuli are in Supporting Data Set 1.
- the testing station comprised a computer, wireless mouse, barcode scanner, and trays containing numbered stimulus containers labeled with bar codes.
- Triangle tests were set up so that subjects were never tested with the same set of stimuli twice in a row, to avoid the situation where subjects remembered their answers from the previous trial.
- Subjects used a barcode scanner to register test data automatically. Subjects took between 20-35 minutes to complete each smell test, with the exception of the UPSIT which took 10-15 minutes.
- a standard inter-trial interval was imposed to avoid odor adaptation by requiring subjects to play a computer game for 20 seconds.
- SMELL-S and SMELL-R were created with four different mixtures of 30 molecules drawn from a panel of 109 monomolecular, intensity-matched chemicals. These odorants were selected from stimuli utilized in previous psychophysical studies (21, 38). We used only molecules that minimally activated the trigeminal system, because such stimuli can be detected by anosmic subjects (39, 40). A characteristic of trigeminal activation by a molecule is a fresh, cold, burning, eucalyptus, pungent, or tickling sensation. We used a lateralization task in which an odorant is applied into only one nostril to assign a lateralization score to each molecule. It is possible to localize the stimulated nostril if it activates the trigeminal system.
- Stimuli for the vial threshold tests and SMELL-S were presented to subjects with amber glass vials (height: 95 mm, diameter: 28 mm).
- Stimuli for SMELL-R were presented to subjects with amber glass jars (height: 51 mm, diameter: 55 mm). The complete list of stimuli used in this study is in Supporting Data Set 1.
- Threshold tests were administered as a series of triangle tests. Subjects were presented with three vials: two contained 1 ml solvent (paraffin oil) and one contained either phenylethyl alcohol or butanol diluted in solvent in a total volume of 1 ml. Tests comprised 16 different concentrations generated by serial dilutions (1:2) of either odorant in paraffin oil, with the starting concentrations at 0.0313% for phenylethyl alcohol (vial) and 0.25% for butanol (vial). The subject was prompted to sniff each vial and select the one with the strongest perceived odor using an adaptive staircase procedure commonly used in smell testing (23).
- the procedure started at the lowest concentration. If they identified an incorrect vial, the second next higher concentration was presented and so on, until they identified the correct vial. If the subjects identified the correct vial, they were retested at the same concentration. If they identified the correct vial in this retest, they were tested at the next lower concentration. If they identified an incorrect vial, they were tested at the next higher concentration.
- a reversal is when the direction in which the concentration is changed reverses. The procedure ended after the seventh reversal, or until the subject failed the level with the highest concentration twice in row, or succeeded with the lowest concentration level 5 times in row.
- the threshold was defined as the average of the concentrations at which the last two reversals occurred. If the highest concentration were not correctly identified twice, the score was 1. If the lowest was identified 5 times in a row, the score was 16.
- SMELL-S (v1) and SMELL-S (v2) we prepared 19 serial dilutions in paraffin oil (1:2) of two different mixtures of 30 monomolecular odorants and used the last 16 dilutions, such that the tests ranged from easiest (level 1, 1:8 dilution) to most difficult (level 16, 1:262,144 dilution). Subjects were asked to sniff 3 vials, one of which was filled with 1 ml of a mixture of 30 components, and the other two were filled with 1 ml of solvent (paraffin oil). Subjects were instructed to pick out the one vial with the strongest perceived odor. If they were unable to detect any difference among the three vials, they were prompted to choose one at random.
- the procedure started at the lowest concentration (level 16).
- SMELL-R (v1) and SMELL-R (v2) we prepared 16 pairs of mixtures of 30 monomolecular odorants that differ in how many components the two mixtures in the pair share from 0% (easiest; level 1) to 96.7% (most difficult; level 16).
- ODD odor components of a mixture of 30 molecules
- CONTROL odor components from another mixture of 30 components that did not change in composition across the levels.
- Increasing the level of difficulty by one point correspond to an addition of 2 overlapping molecules between both mixtures, except from level 15 to 16, where we added only 1 shared molecule.
- Stimuli (8 ml) were introduced into jars containing absorbent cotton pads. Subjects were asked to sniff the contents of 3 jars, one of which was filled with 8 ml of a mixture of 30 components, and the other two were filled with 8 ml of a mixture of 30 components with different degree of overlap with the first jar. Subjects were instructed to pick out the odd jar. If they were unable to detect any difference among the three jars, they were prompted to choose one at random. Triangle tests started at a medium difficulty (level 8). If they identified the incorrect jar, the next easier level was presented. We calculated the SMELL-R resolution score following the same adaptive staircase procedure described above. For each subject, we measured the olfactory resolution with two versions of the tests, SMELL-R (v1) and SMELL-R (v2), which differed only in the chemical constituents of the two sets of mixtures.
- the Sniffin' Sticks (23) threshold phenylethyl alcohol threshold test is a commercial product that uses felt-tip pens filled with odorant instead of ink for odor presentation.
- the test comprises pens containing 16 serial dilutions of phenylethyl alcohol (1:2) in solvent (propylene glycol) with a starting concentration of 4%.
- the test was administered as a triangle test. Three pens were presented to the subjects by the investigator in a randomized order. Two pens contained the solvent only, and the third pen contained the diluted odorant.
- the University of Pennsylvania Smell Identification Test (UPSIT, marketed as the Smell Identification Test by Sensonics International) is a well-validated and self-administered smell identification test widely used in the USA (43).
- the test consists of 4 different 10-page booklets, with a total of 40 monomolecular stimuli. On each page, there is a different “scratch and sniff” strip which is embedded with a microencapsulated odorant. There are also four choice multiple-choice questions on each page. Subjects used the tip of a pencil to release the smell of the stimuli.
- the Taiwanese subjects were given a reference sheet on which the English multiple-choice questions in the UPSIT booklets were translated into Chinese by R.-S. J. ( FIG. 5B ) (18).
- ICC Intra-class Correlation Coefficient
- Taiwanese IRB Protocol #JHS-0901
- the North American subjects were tested at The Rockefeller University Hospital, and the Taiwanese subjects were tested in the Department of Otolaryngology at Taichung Veterans General Hospital.
- the experimental design was the same in both institutions.
- Each subject came to the test site for a single visit, during which subjects performed the SMELL-R (v2) and UPSIT, separated by a 10 minute break, in randomized order ( FIG. 5A ).
- SMELL-S and SMELL-R olfactory tests not influenced by odor-specific insensitivity or prior olfactory experience
- SMELL-R MIXTURES CID Odor name Dilution SMELL-R (v1) first mix 14514 2-acetyl-5-methylfuran 1/1000 first mix 12741 2-decanone 1/10 first mix 7720 2-ethyl-1-hexanol 1/1,000 first mix 13187 2-nonanone 1/100 first mix 6054 2-phenylethanol 1/100 first mix 89440 6-acetyl-1,1,2,4,4,7- 1/10 hexamethyltetralin first mix 7410 acetophenone 1/1,000 first mix 16324 allyl butyrate 1/1000 first mix 261 butyraldehyde 1/1,000 first mix 10364 carvacrol 1/1000 first mix 7335 carvyl acetate 1/1000 first mix 2969 decanoic acid 1/10 first mix 660 dihydrocoumarin 1/100 first mix 62378 dihydrojasmone 1/10 first mix 6826 dimethyl anthranilate 1/100 first mix 7583 diphenyl ether
- SMELL-S and SMELL-R olfactory tests not influenced by odor-specific insensitivity or prior olfactory experience
- SMELL-S MIXTURES CID Molecule Dilution SMELL-S (v1) 14514 2-acetyl-5-methylfuran 1/1000 12741 2-decanone 1/10 7720 2-ethyl-1-hexanol 1/1,000 13187 2-nonanone 1/100 6054 2-phenylethanol 1/100 89440 6-acetyl-1,1,2,4,4,7-hexamethyltetralin 1/10 7410 acetophenone 1/1,000 16324 allyl butyrate 1/1000 261 butyraldehyde 1/1,000 10364 carvacrol 1/1000 7335 carvyl acetate 1/1000 2969 decanoic acid 1/10 660 dihydrocoumarin 1/100 62378 dihydrojasmone 1/10 6826 dimethyl anthranilate 1/100 7583 diphenyl ether 1/1,000 24020 ethyl 2-methylbutyrate 1/1000 12327 ethyl undecanoate 1
- SMELL-S and SMELL-R olfactory tests not influenced by odor-specific insensitivity or prior olfactory experience
- Table SMELL-R Combinations This Table lists the composition of stimuli for all 16 levels of SMELL-R (v1) and SMELL-R (v2).
- the ODD odor is presented in a single vial
- the CONTROL odor is presented in two identical vials.
- the task is for the subject to sniff the three vials and select the one vial containing the ODD odor. All mixtures have equal volumes of each component.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Neurology (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Fats And Perfumes (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/628,075 US20210145348A1 (en) | 2017-07-03 | 2018-07-03 | Compositions and methods for a universal clinical test for olfactory dysfunction |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762528420P | 2017-07-03 | 2017-07-03 | |
US16/628,075 US20210145348A1 (en) | 2017-07-03 | 2018-07-03 | Compositions and methods for a universal clinical test for olfactory dysfunction |
PCT/US2018/040704 WO2019010172A1 (fr) | 2017-07-03 | 2018-07-03 | Compositions et procédés destinés à un test clinique universel pour un dysfonctionnement olfactif |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/040704 A-371-Of-International WO2019010172A1 (fr) | 2017-07-03 | 2018-07-03 | Compositions et procédés destinés à un test clinique universel pour un dysfonctionnement olfactif |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/160,624 Continuation US20230172525A1 (en) | 2017-07-03 | 2023-01-27 | Compositions and methods for a universal clinical test for olfactory dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210145348A1 true US20210145348A1 (en) | 2021-05-20 |
Family
ID=64950333
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/628,075 Abandoned US20210145348A1 (en) | 2017-07-03 | 2018-07-03 | Compositions and methods for a universal clinical test for olfactory dysfunction |
US18/160,624 Pending US20230172525A1 (en) | 2017-07-03 | 2023-01-27 | Compositions and methods for a universal clinical test for olfactory dysfunction |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/160,624 Pending US20230172525A1 (en) | 2017-07-03 | 2023-01-27 | Compositions and methods for a universal clinical test for olfactory dysfunction |
Country Status (3)
Country | Link |
---|---|
US (2) | US20210145348A1 (fr) |
EP (1) | EP3648613A4 (fr) |
WO (1) | WO2019010172A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USD973523S1 (en) | 2021-06-14 | 2022-12-27 | U-Smell-It | Multi-odorant testing device |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111579724B (zh) * | 2020-06-01 | 2022-07-12 | 中国标准化研究院 | 一种麻和辣阈上感觉敏感度快速分类方法、装置及应用 |
WO2022028949A1 (fr) * | 2020-08-05 | 2022-02-10 | Mkg Consulting Ug (Haftungsbeschränkt) | Système de test pandémique rapide |
CA3201385A1 (fr) * | 2020-08-26 | 2022-03-03 | Evon Medics, Llc | Systemes et procedes de test olfactif |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6844302B1 (en) * | 2000-10-27 | 2005-01-18 | International Flavors & Fragrances Inc. | Encapsulated flavor and fragrance |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5800897A (en) * | 1996-01-25 | 1998-09-01 | Eastman Chemical Company | Air freshener composition containing a fiber pad |
AU2004292536A1 (en) * | 2003-11-21 | 2005-06-09 | Arena Pharmaceuticals, Inc. | Methods for producing olfactory GPCRS |
JP5015797B2 (ja) * | 2004-12-22 | 2012-08-29 | シムライズ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツト・ゲゼルシヤフト | アクリレート及びアセトフェノンをベースとする水素用着臭剤 |
US20070077204A1 (en) * | 2005-06-10 | 2007-04-05 | The Trustees Of Columbia University In The City Of New York | Olfactory identification tests for cognitive diseases and disorders |
EP2174585A1 (fr) * | 2008-09-29 | 2010-04-14 | Carlo Maremmani | Kit de test d'identification olfactive pour déterminer des troubles neurologiques |
US9959392B2 (en) * | 2011-09-07 | 2018-05-01 | Yeda Research And Development Co. Ltd. | Olfactory signature and odorant mixture having the same |
EP2792302A1 (fr) * | 2013-04-17 | 2014-10-22 | Institut Pasteur | Moyens olfactifs utiles dans le diagnostic et le traitement de la dépression |
US10980467B2 (en) * | 2015-04-03 | 2021-04-20 | Olfaxis, Llc | Apparatus, method, and system for testing human olfactory systems |
JP6949838B2 (ja) * | 2015-10-29 | 2021-10-13 | フィルメニッヒ インコーポレイテッドFirmenich Incorporated | 高甘味度甘味料 |
-
2018
- 2018-07-03 EP EP18828254.5A patent/EP3648613A4/fr active Pending
- 2018-07-03 US US16/628,075 patent/US20210145348A1/en not_active Abandoned
- 2018-07-03 WO PCT/US2018/040704 patent/WO2019010172A1/fr unknown
-
2023
- 2023-01-27 US US18/160,624 patent/US20230172525A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6844302B1 (en) * | 2000-10-27 | 2005-01-18 | International Flavors & Fragrances Inc. | Encapsulated flavor and fragrance |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USD973523S1 (en) | 2021-06-14 | 2022-12-27 | U-Smell-It | Multi-odorant testing device |
USD995337S1 (en) | 2021-06-14 | 2023-08-15 | Derek Kalev Toomre | Multi-odorant testing device |
Also Published As
Publication number | Publication date |
---|---|
EP3648613A4 (fr) | 2021-03-31 |
US20230172525A1 (en) | 2023-06-08 |
EP3648613A1 (fr) | 2020-05-13 |
WO2019010172A1 (fr) | 2019-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230172525A1 (en) | Compositions and methods for a universal clinical test for olfactory dysfunction | |
Le Bon et al. | Psychophysical evaluation of chemosensory functions 5 weeks after olfactory loss due to COVID-19: a prospective cohort study on 72 patients | |
Cameron et al. | Odor identification testing in children and young adults using the smell wheel | |
Sorokowska et al. | Changes of olfactory abilities in relation to age: odor identification in more than 1400 people aged 4 to 80 years | |
Allen et al. | Flavoring chemicals in e-cigarettes: diacetyl, 2, 3-pentanedione, and acetoin in a sample of 51 products, including fruit-, candy-, and cocktail-flavored e-cigarettes | |
Veyseller et al. | Connecticut (CCCRC) olfactory test: normative values in 426 healthy volunteers | |
JP6666327B2 (ja) | 純粋嗅剤に対する嗅覚検知閾値の左右差を検知するための改良された方法 | |
Doty | Olfactory dysfunction and its measurement in the clinic | |
Naka et al. | Clinical significance of smell and taste disorders in patients with diabetes mellitus | |
Doty | Olfactory dysfunction and its measurement in the clinic and workplace | |
White et al. | Metacognitive knowledge of olfactory dysfunction in Parkinson’s disease | |
Coucke et al. | Δ9-Tetrahydrocannabinol concentrations in exhaled breath and physiological effects following cannabis intake–A pilot study using illicit cannabis | |
Landis et al. | Olfactory function improves following hemodialysis | |
Maremmani et al. | The validity and reliability of the Italian Olfactory Identification Test (IOIT) in healthy subjects and in Parkinson's disease patients | |
Rodríguez-Violante et al. | Comparing the accuracy of different smell identification tests in Parkinson’s disease: relevance of cultural aspects | |
Hayes et al. | Evaluation of smoking on olfactory thresholds of phenyl ethyl alcohol and n-butanol | |
EP2174585A1 (fr) | Kit de test d'identification olfactive pour déterminer des troubles neurologiques | |
KR102297693B1 (ko) | 후각 검사용 키트 | |
Fasunla et al. | Evaluation of olfactory and gustatory function of HIV infected women | |
Froutan et al. | Lead toxicity: a probable cause of abdominal pain in drug abusers | |
Tran et al. | Development and validation of the Vietnamese smell identification test | |
Picillo et al. | Validation of an Italian version of the 40-item University of Pennsylvania Smell Identification Test that is physician administered: our experience on one hundred and thirty-eight healthy subjects. | |
Gellrich et al. | Assessment of olfactory function in children and adolescents: An overview | |
Risby et al. | Breath analysis—past, present and future: a special issue in honour of Michael Phillips’ 70th birthday | |
Labianca | Non-foolproof nature of slope detection technology in the Dräger Alcotest 9510 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |